Treating diabetes mellitus in Prader-Willi syndrome with Exenatide

Diabetes Research and Clinical Practice

Volumn 92, Issue 1, 2011, Pages

  Seetho, Ian W ^a   Jones, Gavin ^b   Thomson, George A ^c   Fernando, Devaka J S ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b CHESTERFIELD ROYAL HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetes mellitus; Exenatide; Ghrelin; Obesity; Prader Willi syndrome

Indexed keywords

EXENDIN 4; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN GLARGINE; METFORMIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DECREASED APPETITE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERPHAGIA; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRADER WILLI SYNDROME; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; DIABETES MELLITUS; FEMALE; GHRELIN; HUMANS; PEPTIDES; PRADER-WILLI SYNDROME; VENOMS; YOUNG ADULT;

EID: 79954591361     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.12.009     Document Type: Article

References (10)

1. Donaldson M.D.C., Chu C.E., Cooke A., Wilson A., Greene S.A., Stephenson J.B.P. The Prader-Willi syndrome. Arch Dis Child 1994, 70:58-63.
2. Cassidy S.B., Driscoll D.J. Prader-Willi syndrome. Eur J Hum Genet 2009, 17:3-13.
3. Schnabel C.A., Wintle M., Kolterman O. Metabolic effects of the incretin mimetic Exenatide in the treatment of type 2 diabetes. Vasc Health Risk Manag 2006, 2(1):69-77.
4. Cummings D.E., Overduin J. Gastrointestinal regulation of food intake. J Clin Invest 2007, 117:13-23.
5. Haqq A.M., Farooqi I.S., O'Rahilly S., Stadler D.D., Rosenfeld R.G., Pratt K.L., et al. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader Willi syndrome. J Clin Endocrinol Metab 2003, 88(1):174-178.
6. Goldstone A.P., Thomas E.L., Brynes A.E., Castroman G., Edwards R., Ghatei M.A., et al. Elevated fasting plasma ghrelin in Prader-Willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J Clin Endocrinol Metab 2004, 89:1718-1726.
7. Goldstone A.P., Patterson M., Kalingag N., Ghatei M.A., Brynes A.E., Bloom S.R., et al. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005, 90:2681-2690.
8. Ahima R.S. Antagonism of ghrelin for glycemic control in type 2 diabetes mellitus?. Endocrinology 2007, 148:5173-5174.
9. Pérez-Tilve D., González-Matías L., Alvarez-Crespo M., Leiras R., Tovar S., Diéguez C., et al. Exendin-4 potently decreases ghrelin levels in fasting rats. Diabetes 2007, 56(1):143-151.
10. Viardot A., Sze L., Purtell L., Lohghnan G., Smith E., Herzog H., et al. Exenatide lowers postprandial glycaemia and increased satiety without side effects in Prader Willi syndrome. Diabetologia 2010, 53(Suppl. 1):S66.